Professor Finlay Macrae AO, MBBS, MD, FRACP, FRCP, AGAF, MWGO is Principal Fellow and Professor, Department of Medicine, University of Melbourne, and Head of Colorectal Medicine and Genetics, The Royal Melbourne Hospital.
He is a lead clinician in the Familial Cancer Clinic at The Royal Melbourne Hospital, the state’s busiest in familial bowel cancer. He was a member of the Cancer Council Australia’s committee reviewing the NHMRC Guidelines for the Prevention, Screening, and Management of Colorectal, chairing the contemporary section on primary prevention. He is a member of the Clinical Advisory Group to the Australian National Bowel Cancer Screening Program
He is a Councillor for the International Society of Gastrointestinal Hereditary Tumours (InSiGHT), and through his department, manages the world’s central LOVD databases of DNA variation in the MMR and other genes predisposing to colorectal cancer, recently extending to ClinGen for ClinVar; member of Steering Committee of the National Institutes of Health (USA) Colon Cancer Family Registry; the Advisory Committee of the European Prospective Lynch Syndrome Database; the International Scientific Advisory Committee of the Global Variome, now merged with HUGO. He is the International Vice- Chairman of the CAPP organization for randomised controlled trials of aspirin chemoprevention in mismatch repair gene carriers, leading the Australian contribution to CAPP3. CAPP2 was nominated as the Advancement of the Year in Cancer Prevention by the American Society of Clinical Oncology
In 2021, he was awarded the Gastroenterological Society of Australia’s Distinguished Research Prize.
